Cobitolimod - InDex Pharmaceuticals

Drug Profile

Cobitolimod - InDex Pharmaceuticals

Alternative Names: Antisense oligonucleotide NF-KB-p65; DIMS-0150; Kappaproct

Latest Information Update: 14 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InDex Pharmaceuticals
  • Class Anti-inflammatories; Antiulcers; Oligodeoxyribonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • Discontinued Brain oedema

Most Recent Events

  • 04 May 2018 Early research in Ulcerative colitis (Controlled release) in Sweden (PO, Capsule)
  • 28 Mar 2018 InDex Pharmaceuticals receives patent allowance for cobitolimod in Japan
  • 06 Dec 2017 Discontinued - Phase-I for Brain oedema in Sweden (Rectal) (Index Pharmaceuticals Pipeline, December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top